

Electronic Supplementary Information

Copper- or Iron-catalyzed stereoselective methylation of enamides

with dicumyl peroxide as the methyl source

Fukuan Zhang, Haidong Liu, Xin-Jian Jia, Lin Li, Yi Liang, Xuzhong Luo,
Haiqing Luo*

*^a Department of Chemistry & Chemical Engineering, Gannan Normal University,
Ganzhou 341000, China
E-mail: luohaiq@sina.com*

Table of Contents


1. General experimental methods	3
2. General procedures for the synthesis of methylated enamides.....	3
3. Free radical capture experiments	4
4. Competitive reaction studies	4
5. The method of crystal synthesis	5
6. Structure analysis X-ray crystallography of 2a	5
7. References	6
8. Characterization data for the products.....	7
9. ¹ H NMR and ¹³ C NMR spectra of the products.....	15

1. General experimental methods

Proton nuclear magnetic resonance (^1H NMR) and carbon nuclear magnetic resonance (^{13}C NMR) spectroscopy were performed on a Bruker Advance 300, 400 and 500 NMR spectrometers. Chemical shifts ^1H NMR spectra are reported as in units of parts per million (ppm) downfield from SiMe_4 (0.0) and relative to the signal of chloroform-*d* ($\delta = 7.264$, singlet). Multiplicities were given as: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); ddd (doublet of doublets of doublets); dddd (doublet of doublets of doublets of doublets); dt (doublet of triplets); m (multiplets) and etc. The number of protons (*n*) for a given resonance is indicated by *n*H. Coupling constants are reported as a *J* value in Hz. Carbon nuclear magnetic resonance spectra (^{13}C NMR) are reported as δ in units of parts per million (ppm) downfield from SiMe_4 (0.0) and relative to the signal of chloroform-*d* ($\delta = 77.03$, triplet). High resolution mass spectral analysis (HRMS) was performed on LCMS Q-TOF (SHIMADZU Corporation) ESI spectrometer.


Unless otherwise noted, all reagents were purchased from commercial suppliers (Energy Chemistry; Tansoole) and used without further purification. All enamides were prepared using existing methods.^{1,2}

2. General procedures for the synthesis of methylated enamides




A sealed tube was charged with enamides **1** (0.3 mmol), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ or FeCl_2 (5 mol%) and dicumyl peroxide (0.6 mmol). Then, 2.0 mL of *t*-BuOH was added as solvent. The mixture was kept stirring under air at 120 °C or 130 °C for 18 h. After completion of the reaction (confirmed by checking TLC), the mixture was poured into water (15 mL) and was extracted with ethylacetate (3 x 15 mL). The combined organic layers were washed with brine (2 x 15 mL) and dried over Na_2SO_4 . The residue was purified by flash chromatography on silica gel, eluting with ethylacetate/petroleum ether (1:12~1:6 v/v) to afford the desired products **2**.


3. Free radical capture experiments



A sealed tube was charged with enamides **1** (0.3 mmol), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ or FeCl_2 (5 mol%), dicumyl peroxide (0.6 mmol) and 2,2,6,6-tetramethyl-1-piperidin-1-yl methyl ether (TEMPO) (0.6 mmol). Then, 2.0 mL of *t*-BuOH was added as solvent. The mixture was kept stirring under air at 120 °C for 18 h. After the reaction finished, inspection of the crude reaction mixture by GC-MS.



4. Competitive reaction studies



Enamide **1e** (0.2 mmol, 1.0 equiv), enamide **1i** (0.2 mmol, 1.0 equiv), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ or FeCl_2 (5 mol%) and dicumyl peroxide (0.4 mmol), were dissolved in *t*-BuOH (2.0 mL). The mixture was kept stirring under air at 120 °C for 30 minutes. After the reaction finished, the mixture was removed in vacuum and the product was pale yellow oil. Inspection of the crude reaction mixture by ^1H NMR spectroscopy showed that the ratio of **2e** to **2i** was approximately 0.94 or 0.92.

5. The method of crystal synthesis

Synthesis was carried out by reaction of **1a** (0.3 mmol), Cu(OAc)₂·H₂O (5 mol%) and dicumyl peroxide (0.6 mmol) in *t*-BuOH (2.0 mL) under air at 120 °C for 18 h. Single crystals suitable for X-ray analysis were grown from ethylacetate solution of **2a** by slow vapor diffusion of petroleum ether.

6. Structure analysis X-ray crystallography of **2a**




Figure S1. Thermal ellipsoid plot of the crystal structure of **2a**

Identification code	2a
Empirical formula	C ₁₈ H ₁₉ NO
Formula weight	265.34
Temperature	100.15 K
Crystal system	monoclinic
Space group	P2 ₁ /c


Unit cell dimensions	a	9.5009(11) Å
	b	9.4353(11) Å
	c	16.3857(17) Å
	α	90 °
	β	90.365(11) °
	γ	90 °
Volume		1468.8(3) Å ³
Z		4
Density (calculated)		1.200 g/cm ³
Absorption coefficient		0.574 μ/mm ⁻¹
F(000)		568.0
Crystal size		0.1 × 0.1 × 0.1 /mm ³
Theta range for data collection		9.308 to 131.902
Index ranges		-9 ≤ h ≤ 11, -9 ≤ k ≤ 11, -19 ≤ l ≤ 19
Reflections collected		8504
Independent reflections		2407 [R _{int} = 0.0508, R _{sigma} = 0.0462]
Data / restraints / parameters		2407/0/183
Goodness-of-fit on F ²		1.043
Final R indices [I > 2σ(I)]		R ₁ = 0.0686, wR ₂ = 0.1927
R indices (all data)		R ₁ = 0.0793, wR ₂ = 0.2049
Largest diff. peak and hole		0.34/-0.25 e Å ⁻³

7. References

- 1 X. Li, K. Sun, W. Shen, Y. Zhang, M.-Z. Lu, X. Luo, and H. Luo, Rhodium(III)-Catalyzed Direct C–H Arylation of Various Acyclic Enamides with Arylsilanes, *Org. Lett.* 2021, **23**, 31-36.
- 2 X.-H. Chang, Z.-L. Wang, M. Zhao, C. Yang, J.-J. Li, W.-W. Ma, and Y.-H. Xu, Synthesis of Functionalized Vinylsilanes via Metal-Free Dehydrogenative Silylation of Enamides, *Org. Lett.*, 2020, **22**, 1326-1330.

8. Characterization data for the products


(*E*)-*N*-benzyl-*N*-(1-phenylprop-1-en-1-yl)acetamide (**2a**)



Yellow oil ([Cu] 63.7 mg, 80% yield; [Fe] 60.5 mg, 76% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.42 – 7.31 (m, 3H), 7.29 – 7.22 (m, 5H), 7.21 – 7.18 (m, 2H), 5.43 (q, *J* = 7.3 Hz, 1H), 4.49 (s, 2H), 2.21 (s, 3H), 1.76 (d, *J* = 7.3 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.8, 139.1, 137.5, 134.6, 128.7, 128.6, 128.4, 128.3, 128.1, 127.0, 126.7, 48.9, 22.0, 14.3;

HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₈H₁₉NONa⁺ 288.1359, found 288.1366.


(*E*)-*N*-benzyl-*N*-(1-(*p*-tolyl)prop-1-en-1-yl)acetamide (**2b**)



Yellow oil ([Cu] 71.2 mg, 85% yield; [Fe] 64.5 mg, 77% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.29 – 7.23 (m, 3H), 7.22 – 7.20 (m, 2H), 7.20 (s, 2H), 7.18 – 7.14 (m, 2H), 5.38 (q, *J* = 7.3 Hz, 1H), 4.48 (s, 2H), 2.38 (s, 3H), 2.20 (s, 3H), 1.76 (d, *J* = 7.3 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.9, 139.1, 138.2, 137.6, 131.7, 129.1, 128.7, 128.5, 128.1, 126.9, 126.1, 48.9, 22.0, 21.1, 14.3;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₂₂NO⁺ 280.1696, found 280.1704.

(*E*)-*N*-benzyl-*N*-(1-(*o*-tolyl)prop-1-en-1-yl)acetamide (**2c**)




Yellow oil ([Cu] 57.0 mg, 68% yield; [Fe] 60.3 mg, 72% yield): **¹H NMR** (400 MHz,

CDCl₃) δ 7.31 – 7.21 (m, 6H), 7.20 – 7.13 (m, 3H), 5.59 (q, J = 7.1 Hz, 1H), 4.44 (s, 2H), 2.40 (s, 3H), 2.15 (s, 3H), 1.55 (d, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.9, 138.4, 137.7, 137.3, 133.8, 130.6, 129.3, 128.4, 128.1, 128.0, 126.8, 126.0, 125.8, 48.2, 22.2, 19.5, 14.2;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₂₂NO⁺ 280.1696, found 280.1705.


(E)-N-(1-([1,1'-biphenyl]-4-yl)prop-1-en-1-yl)-N-benzylacetamide (2d)



Yellow oil ([Cu] 78.9 mg, 77% yield; [Fe] 60.3 mg, 76% yield): ¹H NMR (400 MHz, CDCl₃) δ 7.69 – 7.65 (m, 4H), 7.52 – 7.49 (m, 2H), 7.43 – 7.41 (m, 1H), 7.40 – 7.38 (m, 2H), 7.33 – 7.26 (m, 5H), 5.51 (q, J = 7.3 Hz, 1H), 4.60 (s, 2H), 2.27 (s, 3H), 1.87 (d, J = 7.4 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.8, 140.9, 140.0, 138.8, 137.5, 133.5, 129.6, 128.9, 128.7, 128.0, 127.5, 127.0, 127.0, 126.9, 126.8, 49.0, 22.0, 14.4;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₄NO⁺ 342.1852, found 342.1864.


(E)-N-benzyl-N-(1-(4-methoxyphenyl)prop-1-en-1-yl)acetamide (2e)



Yellow oil ([Cu] 64.69 mg, 73% yield; [Fe] 65.5 mg, 74% yield): ¹H NMR (400 MHz, CDCl₃) δ 7.26 – 7.20 (m, 4H), 7.18 – 7.16 (m, 3H), 6.91 – 6.88 (m, 2H), 5.32 (q, J = 7.3 Hz, 1H), 4.46 (s, 2H), 3.82 (s, 3H), 2.16 (s, 3H), 1.73 (d, J = 7.2 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 171.0, 159.6, 139.0, 137.8, 130.0, 128.9, 128.2, 127.1, 125.6, 114.0, 113.7, 55.3, 49.1, 22.2, 14.5;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₂₂NO₂⁺ 296.1645, found 296.1656.


(E)-N-benzyl-N-(1-(3-methoxyphenyl)prop-1-en-1-yl)acetamide (2f)



Yellow oil ([Cu] 67.3 mg, 76% yield; [Fe] 62.1 mg, 70% yield): $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.44 – 7.10 (m, 6H), 6.90 – 6.82 (m, 2H), 6.77 – 6.73 (m, 1H), 5.43 (q, J = 7.3 Hz, 1H), 4.49 (s, 2H), 3.77 (s, 3H), 2.18 (s, 3H), 1.77 (d, J = 5.5 Hz, 3H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 170.8, 159.6, 139.1, 137.6, 136.1, 129.4, 128.8, 128.1, 127.0, 126.9, 121.1, 114.4, 113.5, 55.1, 49.1, 22.0, 14.4;

HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{22}\text{NO}_2^+$ 296.1645, found 296.1656.


(E)-N-benzyl-N-(1-(2,4-dimethoxyphenyl)prop-1-en-1-yl)acetamide (2g)



Yellow oil ([Cu] 57.6 mg, 59% yield; [Fe] 69.3 mg, 71% yield): $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.23 – 7.15 (m, 5H), 6.92 (d, J = 8.2 Hz, 1H), 6.46 – 6.43 (m, 2H), 5.40 (q, J = 7.1 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.71 (s, 3H), 2.26 (s, 3H), 1.54 (d, J = 7.1 Hz, 1H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 171.3, 161.1, 158.7, 138.0, 137.1, 132.3, 128.4, 127.8, 126.5, 126.4, 115.8, 104.0, 98.4, 55.2, 55.0, 48.2, 22.2, 14.0;

HRMS (ESI) m/z: $[\text{M}+\text{K}]^+$ Calcd for $\text{C}_{20}\text{H}_{23}\text{NO}_3\text{K}^+$ 364.1310, found 364.1322.

(E)-N-benzyl-N-(1-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)acetamide (2h)




Yellow oil ([Cu] 57.6 mg, 54% yield; [Fe] 66.1 mg, 62% yield): $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.24 – 7.22 (m, 2H), 7.20 – 7.18 (m, 3H), 6.36 (s, 1H), 5.46 (q, J = 7.3 Hz, 1H), 4.53 (s, 2H), 3.84 (s, 3H), 3.76 (s, 6H), 2.14 (s, 3H), 1.80 (d, J = 7.4 Hz, 3H); ^{13}C

NMR (101 MHz, CDCl₃) δ 170.9, 153.1, 139.6, 138.1, 137.6, 130.3, 128.8, 128.1, 127.1, 125.9, 105.9, 60.8, 56.1, 49.7, 22.2, 14.5;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₁H₂₆NO₄⁺ 356.1856, found 356.1869.


(E)-N-benzyl-N-(1-(4-fluorophenyl)prop-1-en-1-yl)acetamide (2i)



White solid ([Cu] 50.2 mg, 59% yield; [Fe] 47.6 mg, 56% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.26 – 7.19 (m, 5H), 7.19 – 7.14 (m, 2H), 7.07 (t, *J* = 8.6 Hz, 2H), 5.42 (q, *J* = 7.3 Hz, 1H), 4.47 (s, 2H), 2.18 (s, 3H), 1.73 (d, *J* = 7.3 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.7, 162.3 (d, *J* = 248.8 Hz), 138.30, 137.4, 130.7 (d, *J* = 3.3 Hz), 130.4 (d, *J* = 8.2 Hz), 128.7, 128.1, 127.1, 126.7, 115.5 (d, *J* = 21.6 Hz), 49.0, 22.0, 14.3;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₈H₁₉NOF⁺ 284.1445, found 284.1455.


(E)-N-benzyl-N-(1-(4-chlorophenyl)prop-1-en-1-yl)acetamide (2j)



Yellow oil ([Cu] 54.9 mg, 61% yield; [Fe] 64.75 mg, 72% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.36 – 7.34 (m, 2H), 7.26 – 7.21 (m, 3H), 7.19 – 7.15 (m, 4H), 5.45 (q, *J* = 7.3 Hz, 1H), 4.47 (s, 2H), 2.17 (s, 3H), 1.74 (d, *J* = 7.4 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.8, 138.1, 137.3, 134.1, 133.1, 130.5, 129.9, 128.7, 128.1, 127.4, 127.1, 49.0, 22.0, 14.4;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₈H₁₉NOCl⁺ 300.1150, found 300.1162.


(E)-N-benzyl-N-(1-(4-bromophenyl)prop-1-en-1-yl)acetamide (2k)



Yellow oil ([Cu] 68.2 mg, 65% yield; [Fe] 65.1 mg, 63% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.51 – 7.49 (m, 2H), 7.26 – 7.20 (m, 3H), 7.17 – 7.14 (m, 2H), 7.12 – 7.08 (m, 2H), 5.45 (q, *J* = 7.3 Hz, 1H), 4.46 (s, 2H), 2.16 (s, 3H), 1.73 (d, *J* = 7.4 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.7, 138.2, 137.3, 133.6, 131.6, 130.2, 128.7, 128.1, 127.4, 127.1, 122.3, 49.0, 22.0, 14.4;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₈H₁₉NOBr⁺ 344.0645, found 344.0659.


(*E*)-N-benzyl-N-(1-(3-bromophenyl)prop-1-en-1-yl)acetamide (2l)



Yellow oil ([Cu] 69.2 mg, 67% yield; [Fe] 67.1 mg, 65% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.46 (d, *J* = 7.9 Hz, 1H), 7.36 (t, *J* = 1.7 Hz, 1H), 7.27 – 7.21 (m, 4H), 7.19 – 7.15 (m, 3H), 5.47 (q, *J* = 7.4 Hz, 1H), 4.48 (s, 2H), 2.17 (s, 3H), 1.76 (d, *J* = 7.4 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.8, 137.9, 137.3, 136.9, 131.4, 130.0, 128.7, 128.2, 128.0, 127.3, 127.2, 122.6, 49.1, 22.1, 14.4;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₈H₁₉NOBr⁺ 344.0645, found 344.0659.

(*E*)-N-benzyl-N-(1-(4-iodophenyl)prop-1-en-1-yl)acetamide (2m)




Yellow oil ([Cu] 55.2 mg, 48% yield; [Fe] 63.4 mg, 54% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.72 – 7.68 (m, 2H), 7.27 – 7.21 (m, 3H), 7.18 – 7.13 (m, 2H), 6.98 (d, *J* = 8.4 Hz, 2H), 5.45 (q, *J* = 7.3 Hz, 1H), 4.47 (s, 2H), 2.16 (s, 3H), 1.74 (d, *J* = 7.4 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.8, 138.3, 137.7, 137.3, 134.3, 130.4, 128.7,

128.2, 127.5, 127.1, 94.1, 49.1, 22.1, 14.5;

HRMS (ESI) m/z: $[M+H]^+$ Calcd for $C_{18}H_{19}NOI^+$ 392.0506, found 392.0524.


(E)-N-benzyl-N-(1-(3-iodophenyl)prop-1-en-1-yl)acetamide (2n)



Yellow oil ([Cu] 68.1 mg, 58% yield; [Fe] 71.6 mg, 61% yield): **1H NMR** (400 MHz, $CDCl_3$) δ 7.65 (d, $J = 7.8$ Hz, 1H), 7.54 – 7.53 (m, 1H), 7.25 – 7.22 (m, 3H), 7.19 – 7.15 (m, 3H), 7.10 – 7.08 (m, 1H), 5.46 (q, $J = 7.3$ Hz, 1H), 4.47 (s, 2H), 2.16 (s, 3H), 1.74 (d, $J = 7.4$ Hz, 3H); **^{13}C NMR** (101 MHz, $CDCl_3$) δ 170.7, 137.8, 137.2, 137.2, 136.9, 130.0, 128.7, 128.1, 127.9, 127.8, 127.1, 94.3, 49.1, 22.1, 14.4;

HRMS (ESI) m/z: $[M+H]^+$ Calcd for $C_{18}H_{19}NOI^+$ 392.0506, found 392.0525.


(E)-N-benzyl-N-(1-(4-(trifluoromethyl)phenyl)prop-1-en-1-yl)acetamide (2o)



White solid ([Cu] 53.1 mg, 55% yield; [Fe] 71.0 mg, 71% yield): **1H NMR** (400 MHz, $CDCl_3$) δ 7.67 (d, $J = 8.2$ Hz, 2H), 7.39 (d, $J = 8.1$ Hz, 2H), 7.30 – 7.24 (m, 3H), 7.21 – 7.18 (m, 2H), 5.59 (q, $J = 7.4$ Hz, 1H), 4.52 (s, 2H), 2.22 (s, 3H), 1.81 (d, $J = 7.4$ Hz, 3H); **^{13}C NMR** (101 MHz, $CDCl_3$) δ 170.8, 138.6, 138.3, 137.3, 130.3 (q, $J = 32.5$ Hz), 129.0, 128.8, 128.7, 128.2, 127.2, 125.5 (q, $J = 3.5$ Hz), 123.8 (q, $J = 272.2$ Hz), 49.3, 22.1, 14.4;


HRMS (ESI) m/z: $[M+H]^+$ Calcd for $C_{19}H_{19}NOF_3^+$ 334.1413, found 334.1423.

(E)-N-benzyl-N-(1-(4-cyanophenyl)prop-1-en-1-yl)acetamide (2p)




Yellow oil ([Cu] 64.5 mg, 74% yield; [Fe] 56.6 mg, 65% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.67 – 7.63 (m, 2H), 7.35 – 7.30 (m, 2H), 7.22 – 7.19 (m, 3H), 7.14 – 7.11 (m, 2H), 5.59 (q, *J* = 7.4 Hz, 1H), 4.47 (s, 2H), 2.15 (s, 3H), 1.77 (d, *J* = 7.4 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.7, 139.5, 137.9, 137.0, 132.2, 129.6, 129.2, 128.7, 128.2, 127.3, 126.2, 118.3, 111.9, 49.4, 22.0, 14.5; **HRMS (ESI) m/z:** [M+H]⁺ Calcd for C₁₉H₁₉N₂O⁺ 291.1492, found 291.1506.

(*E*)-*N*-(4-methylbenzyl)-*N*-(1-phenylprop-1-en-1-yl)acetamide (2q)



Yellow oil ([Cu] 60.4 mg, 72% yield; [Fe] 62.9 mg, 75% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.45 – 7.36 (m, 3H), 7.32 – 7.28 (m, 2H), 7.13 – 7.09 (m, 4H), 5.46 (q, *J* = 7.3 Hz, 1H), 4.47 (s, 2H), 2.35 (s, 3H), 2.22 (s, 3H), 1.80 (d, *J* = 7.3 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 170.8, 139.1, 136.5, 134.7, 134.5, 128.8, 128.7, 128.6, 128.4, 128.3, 126.7, 48.7, 22.1, 21.0, 14.4; **HRMS (ESI) m/z:** [M+H]⁺ Calcd for C₁₉H₂₂NO⁺ 280.1696, found 280.1709.

(*E*)-*N*-methyl-*N*-(1-phenylprop-1-en-1-yl)acetamide (2r)




Yellow oil ([Cu] 34.6 mg, 61% yield; [Fe] 30.1 mg, 53% yield): **¹H NMR** (400 MHz, CDCl₃) δ 7.38 – 7.33 (m, 2H), 7.32 – 7.29 (m, 1H), 7.28 – 7.24 (m, 2H), 5.73 (q, *J* = 7.3 Hz, 1H), 2.93 (s, 3H), 2.07 (s, 3H), 1.85 (d, *J* = 7.4 Hz, 3H); **¹³C NMR** (101 MHz, CDCl₃) δ 171.1, 141.6, 134.9, 128.4, 128.3, 128.2, 124.4, 35.0, 21.8, 14.3;

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₂H₁₆NO⁺ 190.1226, found 190.1235.


9. ^1H NMR and ^{13}C NMR spectra of the products

(*E*)-*N*-benzyl-*N*-(1-phenylprop-1-en-1-yl)acetamide (2a)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




(E)-N-benzyl-N-(1-(p-tolyl)prop-1-en-1-yl)acetamide (2b)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(o-tolyl)prop-1-en-1-yl)acetamide (2c)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-(1-([1,1'-biphenyl]-4-yl)prop-1-en-1-yl)-N-benzylacetamide (2d)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(4-methoxyphenyl)prop-1-en-1-yl)acetamide (2e)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(3-methoxyphenyl)prop-1-en-1-yl)acetamide (2f)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(2,4-dimethoxyphenyl)prop-1-en-1-yl)acetamide (2g)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)acetamide (2h)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(4-fluorophenyl)prop-1-en-1-yl)acetamide (2i)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(4-chlorophenyl)prop-1-en-1-yl)acetamide (2j)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(4-bromophenyl)prop-1-en-1-yl)acetamide (2k)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(3-bromophenyl)prop-1-en-1-yl)acetamide (21)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(4-iodophenyl)prop-1-en-1-yl)acetamide (2m)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(3-iodophenyl)prop-1-en-1-yl)acetamide (2n)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(4-(trifluoromethyl)phenyl)prop-1-en-1-yl)acetamide (2o)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-benzyl-N-(1-(4-cyanophenyl)prop-1-en-1-yl)acetamide (2p)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-(4-methylbenzyl)-N-(1-phenylprop-1-en-1-yl)acetamide (2q)

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)



(E)-N-methyl-N-(1-phenylprop-1-en-1-yl)acetamide (2r)

¹H NMR (400 MHz, CDCl₃)



¹³C NMR (101 MHz, CDCl₃)

